Clinical trial
Risperidone and Suicidality in Major Depressive Disorder
NCT00167154 · University of Alabama at Birmingham, Other · Completed
Key facts
| NCT number | NCT00167154 |
|---|---|
| Title | Risperidone and Suicidality in Major Depressive Disorder |
| Official title | Efficacy of Risperidone in the Management of Suicidality in Major Depressive Disorder |
| Lead sponsor | University of Alabama at Birmingham, Other |
| Collaborators | Janssen Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | Risperidone and placebo comparator |
| Enrollment | 30 |
| Start date | Jun 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Aug 1, 2008 |
| First posted | Sep 14, 2005 |
| Last update posted | Jun 10, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: